Skip to main content
MedPathMedPath Home
Clinical Trials/CTIS2023-504403-92-00
CTIS2023-504403-92-00
Active, not recruiting
Phase 1

A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and C

Janssen - Cilag International0 sites200 target enrollmentJune 14, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRelapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)Therapeutic area: Diseases [C] - Neoplasms [C04]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Sponsor
Janssen - Cilag International
Enrollment
200
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 14, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma
NL-OMON53500Janssen-Cilag12
Completed
Not Applicable
A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic SyndromeAcute Myeloid Leukemiabloodcancer10024324
NL-OMON55771MacroGenics Inc.20
Active, not recruiting
Phase 1
A Phase 1/2 Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic SyndromeRelapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic SyndromeMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2015-003813-11-DEMacroGenics, Inc.330
Active, not recruiting
Phase 1
A Phase 1/2 Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic SyndromeRelapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic SyndromeMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2015-003813-11-GBMacroGenics, Inc.330
Active, not recruiting
Phase 1
A Phase 1/2 Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome
EUCTR2015-003813-11-NLMacroGenics, Inc.330